Literature DB >> 10098707

Expression of Th1 and Th2 cytokine mRNAs in freshly isolated peripheral blood mononuclear cells of a patient with cutaneous paragonimiasis.

Y Hatano1, K Katagiri, T Ise, T Yamaguchi, S Itami, Y Nawa, S Takayasu.   

Abstract

Using semiquantitative reverse transcriptase polymerase chain reaction, we examined the levels of various cytokine mRNAs of freshly isolated peripheral blood mononuclear cells (PBMCs) from a cutaneous paragonimiasis patient in the course of successful treatment with praziquantel administration. The pre-treatment levels of Th2 cytokines such as interleukin (IL)-4, IL-5, IL-10 and IL-13 mRNAs in PBMCs of the patient were much higher than those of healthy controls. The levels of IL-4, IL-5 and IL-13 mRNAs slightly elevated on day 2 of the treatment and then declined to the control levels on day 25. The IL-10 mRNA level rapidly decreased after the chemotherapy. In contrast, the mRNA levels of interferon (IFN)-gamma, a Th1 cytokine, remained in the control levels during the course. Peripheral eosinophil counts and levels of total IgE and eosinophil cationic protein in the sera correlated well with the levels of these Th2 cytokine mRNAs. These results suggested the major role of Th2 cytokines in clinical manifestation of human helminthic infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098707     DOI: 10.1016/s0923-1811(98)00057-7

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  2 in total

1.  Elevated IL-5 levels in pleural fluid of patients with paragonimiasis westermani.

Authors:  H Taniguchi; H Mukae; N Matsumoto; M Tokojima; S Katoh; S Matsukura; K Ogawa; S Kohno; Y Nawa
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Elevated levels of thymus and activation-regulated chemokine (TARC) in pleural effusion samples from patients infested with Paragonimus westermani.

Authors:  N Matsumoto; H Mukae; F Nakamura-Uchiyama; J-I Ashitani; K Abe; S Katoh; S Kohno; Y Nawa; S Matsukura
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.